Navigation Links
Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
Date:10/28/2011

DARIEN, Conn., Oct. 28, 2011 /PRNewswire/ -- Cytogel Pharma, LLC. is pleased to announce today the presentation at the American Society of Anesthesiologists of study results and completed analysis of a Phase I study of Cyt-1010.  Cyt-1010 is a proprietary compound and a chemically stabilized analogue of endomorphin 1, a naturally occurring pain modulator.  This trial was designed as a safety study in normal healthy volunteers with additional pharmacodynamic end points.  At the doses tested (up to 0.15 mg/kg) Cyt-1010 was generally well tolerated, and no severe adverse events or evidence of respiratory depression were reported.  The trial included additional tests to measure sensitivity to painful stimuli and statistically significant prolongation of the threshold time for cold pain sensation was recorded at a dose of 0.1 mg/kg.  Cyt-1010 is being developed for the treatment of acute and chronic pain conditions, including neuropathic pain and post-operative pain.

About Cytogel Pharma 

Cytogel Pharma, LLC. is a biopharmaceutical development company based in Darien, Connecticut, focused on developing promising early-stage programs that offer significant potential both as platform technologies and high value product candidates. The company's portfolio includes novel analgesic product candidates and broadly useful polymer and hydrogel drug delivery platform technologies. Cytogel will develop products from these platform technologies to the point of demonstrated value and then license these products to other larger companies for the full scientific and clinical development and subsequent commercialization.  To learn more about Cytogel, please visit our website at www.cytogelpharma.com.

CONTACT: C. Dean Maglaris, 203-966-9867


'/>"/>
SOURCE Cytogel Pharma, LLC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
2. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
3. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
4. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
5. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
6. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
7. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
8. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
9. Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing
10. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
11. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... and Trademark Office (USPTO) has issued a key ... cell-based immunotherapeutic vaccine targeting six tumor antigens that ... US Patent No. 8,871,211, which issued October 28, ... administering a dendritic cell composition comprising peptide epitopes ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/17/2014)... 2014 PCCA received the Autism Hope ... ) program seal for best practices in meeting ... medical practices, materials and goods that meet strict ... Children affected by autism often have unique physical ... ingredients found in food and medicine – for ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... Texas, June 28, 2011 Pharmacy Choice and ... local businesses and pharmacists across the nation and ... care – applauds the Texas Legislature for the ... critical amendments that provide necessary protections for Texans ...
... RESTON, Va., June 28, 2011 The Mirixa ... Stores (CACDS) are pleased to announce that MirixaPro(SM), ... standardized, pharmacy-based patient care service delivery, will be ... 10-year licensing agreement enabling CACDS to use a ...
Cached Medicine Technology:Pharmacy Choice and Access Now Coalition Applauds Passage of Senate Bill 7 During Texas Legislature's Special Session 2Mirixa and CACDS Sign Agreement for Clinical Service Delivery Platform 2Mirixa and CACDS Sign Agreement for Clinical Service Delivery Platform 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... with PureWellness to Provide Online Wellness Platform to All Employees ... ... 29, 2008 -- PureWellness, Inc, a leading provider of ... agreement with Children,s Healthcare of Atlanta, one of the nation,s ...
... pain-free, CHICAGO, July 29 They danced to ... with Jane Fonda and made,jogging their national pastime., ... aren,t,ready to slow down, even if their bodies are. ... than previous generations to seek care when,arthritis develops in ...
... of Wisconsin researchers in Milwaukee have reported that ... a genetic risk factor for Alzheimer,s disease have ... symptoms may appear. , Functional MRI brain ... APOE-4 gene demonstrated significantly reduced functional brain connectivity ...
... with 360 Health & Safety Violations, SALINAS, Calif., ... Center and Windsor Ridge Care Center will,hold a joint ... resident safety. In 2006, both of these homes made ... will be held,simultaneously at eight Bay Area nursing homes ...
... previously thought, researchers say , , MONDAY, July 28 (HealthDay ... of mild cognitive impairment in the elderly population is ... rate of new mild cognitive impairment cases, in this ... Ronald C. Petersen said in a news release. "If ...
... breathing will become even bigger problem, AHA warns , , ... be conducted to determine the exact link between sleep ... the American Heart Association and the American College of ... Circulation . , "There have been a number ...
Cached Medicine News:Health News:Nationally Recognized Pediatric Healthcare System Chooses PureWellness for Employee Wellness Program 2Health News:Nationally Recognized Pediatric Healthcare System Chooses PureWellness for Employee Wellness Program 3Health News:Boomers Not Backing Down From Foot and Ankle Arthritis 2Health News:Boomers Not Backing Down From Foot and Ankle Arthritis 3Health News:Caregivers at 8 Bay Area Nursing Homes Protest Unsafe Resident Conditions in Salinas 2Health News:Rates of Mild Cognitive Impairment Higher Than Expected 2Health News:Rates of Mild Cognitive Impairment Higher Than Expected 3Health News:Experts Urge Research on Sleep Apnea-Heart Disease Link 2
The ELISA test is used for detection and semi quantitation of igG antibodies to proteinase 3(PR3) in human sera, as an aid to the diagnosis is of Wegener's granulomatosis....
... MRSA is a differential medium designed ... of MRSA. Selective agents are incorporated ... most strains of S. epidermidis and ... substrate resulting in mauve colonies, thus ...
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
... is equipped with a 180 watt Xenon short arc ... energy transfer from the lamp to the light guide, ... is equivalent to higher watt bulbs. A new IR ... bulb reduces the amount of heat generated from the ...
Medicine Products: